EARLY Labs

Multi-cancer Screening Platform

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in July 2020 by Michal Mark Danieli, EARLY Labs operates with 1–10 employees. The company has raised $4 million across one funding round. In February 2023, the company garnered significant attention for its work training rats to detect lung cancer with high accuracy by sniffing urine.

Business overview

EARLY Labs is a Bio-Tech company specializing in Volatile Organic Compound-based diagnostics. The company is developing a multi-cancer test platform, initially focusing on lung cancer detection from urine samples, demonstrating high sensitivity and specificity for early-stage detection. This technology aims to simplify cancer screening, making it accessible for at-home or pharmacy use, thereby overcoming barriers associated with traditional, more invasive methods. The platform is designed to expand to colon cancer testing and other cancer types, serving the healthcare and life sciences sectors, including providers and patients.

Strategic signal

EARLY Labs has demonstrated a novel approach to early cancer detection, with news in February and March 2023 highlighting its success in training rats to detect lung cancer from urine samples with high accuracy. This development signals a potential paradigm shift in non-invasive diagnostic methods, offering a promising, accessible, and less invasive screening option that could significantly improve early detection rates and patient outcomes in the oncology field.

Company Intelligence Q&A

When was EARLY Labs founded and by whom?
EARLY Labs was founded in July 2020 by Michal Mark Danieli.
What is the primary focus of EARLY Labs' cancer detection platform?
The platform is currently focused on detecting lung cancer in urine samples, with plans to expand to colon cancer testing by the end of 2024 and other cancer types thereafter.
What is the reported accuracy of EARLY Labs' lung cancer detection method?
In February 2023, the company reported groundbreaking 90% stage I sensitivity and specificity results for lung cancer detection using its urine-based test.
How much capital has EARLY Labs raised?
EARLY Labs has raised $4 million across one funding round.

External links